SEC Comment Letter 0000000000-23-007358 to Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc.
Date: July 11, 2023 · CIK: 0001808898 · Accession: 0000000000-23-007358
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273177
Letter
United States securities and exchange commission logo July 11, 2023 Jerel Banks Chief Executive Officer Benitec Biopharma Inc. 3940 Trust Way Hayward, CA 94545 Re:Benitec Biopharma Inc. Registration Statement on Form S-1 Filed July 7, 2023 File No. 333-273177 Dear Jerel Banks: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Louis Rambo
Show Raw Text
United States securities and exchange commission logo
July 11, 2023
Jerel Banks
Chief Executive Officer
Benitec Biopharma Inc.
3940 Trust Way
Hayward, CA 94545
Re:Benitec Biopharma Inc.
Registration Statement on Form S-1
Filed July 7, 2023
File No. 333-273177
Dear Jerel Banks:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Louis Rambo